ING-006

Idiopathic Pulmonary Fibrosis

PreclinicalActive

Key Facts

Indication

Idiopathic Pulmonary Fibrosis

Phase

Preclinical

Status

Active

Company

First‑in‑class oral GPR84 modulator for IPF with a lipid‑mimetic platform targeting fibrosis and metabolic disease.

Drug	Company	Phase	Status
BIO 300	Humanetics Corp.	Research	Active
Undisclosed	Biossil	Phase 2/3	Active
KITCL27	Kither Biotech	Preclinical	Active
BRS101	BreStem Therapeutics	Phase 1	Active
T03	Treamid Therapeutics	Phase 1	Active
MNM‑siRNA IPF	Interna TX	Preclinical	Active
Pirfenidone	Gyre Therapeutics	Marketed	Approved in China
PIPE-791	Contineum Therapeutics	Phase 1	Phase 1b Planned